TNFRSF8: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of TNFRSF8. The page also collects GeneMedi's different modalities and formats products for TNFRSF8 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TNFRSF8 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
|Gene Official Name||TNFRSF8|
|Gene Alias||CD30, D1S166E, Ki-1|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Cytokine Target, Immuno-oncology Target|
Pre-made TNFRSF8-specific INN-index biosimilar (antibody&conjugates)-itezocabtagene autoleucel, brentuximab vedotin, Brentuximab, Iratumumab
Anti-TNFRSF8 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-INN-879||itezocabtagene autoleucel||TNFRSF8||Engineering T cell|
|GMP-Bios-INN-765||Pre-Made Brentuximab Vedotin Biosimilar, Whole Mab Adc, Anti-Tnfrsf8 Antibody: Anti-CD30/D1S166E/Ki-1 therapeutic antibody Drug Conjugate||brentuximab vedotin||TNFRSF8||Whole mAb ADC|
|GMP-Bios-ab-080||Pre-Made Brentuximab biosimilar, Whole mAb ADC, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody||Brentuximab||TNFRSF8||Whole mAb ADC|
|GMP-Bios-ab-278||Pre-Made Iratumumab biosimilar, Whole mAb, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody||Iratumumab||TNFRSF8||Whole mAb|
Pre-made anti-TNFRSF8 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-TNFRSF8 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TNFRSF8 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T88023-Ab||Anti-TNFRSF8 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody, Cytokine antibody|